acalabrutinib maleate monohydrate

{
  "id": "MLC-T-ONC-000131",
  "term": "acalabrutinib maleate monohydrate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma and adults with mantle cell lymphoma that has already been treated with at least one other therapy. Acalabrutinib maleate monohydrate is used with bendamustine and rituximab to treat adults with mantle cell lymphoma that has not been treated and who cannot receive an autologous stem cell transplant. It is also being studied in the treatment of other types of cancer. Acalabrutinib maleate monohydrate blocks a protein called BTK, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Calquence.",
    "The maleate monohydrate form of acalabrutinib, an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival."
  ],
  "synonyms": [
    "Calquence"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/acalabrutinib-maleate-monohydrate/"
}